A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)

NCT00696709 | Completed Phase 1 Results

• 1 other identifier: V212-004
• Study Type: interventional
• Target: 290
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study was to assess the safety and tolerability of gamma-irradiated varicella-zoster virus (VZV) vaccine A (Part 1) and gamma-irradiated VZV vaccine B and C (Part 2) and to determine if they were immunogenic when administered to healthy individuals, as measured by VZV-specific antibody responses by glycoprotein enzyme-linked immunosorbent assay (gpELISA). The primary hypothesis was that gamma-irradiated VZV vaccine A (Part 1) and gamma-irradiated VZV vaccine B and C (Part 2) would elicit an acceptable VZV-specific immune response. The secondary hypothesis for Part 1 of the study was that heat-treated VZV vaccine would elicit an acceptable VZV-specific immune response.

Conditions

Herpes Zoster

Keywords

Herpes Zoster (Shingles)

Outcome Measures

Primary Outcomes (8)

• Part 1: Geometric Mean Fold Rise of the Varicella-Zoster Virus (VZV)-Specific Immune Responses Measured by Glycoprotein Enzyme-Linked Immunosorbent Assay in Gamma-Irradiated VZV Vaccine A Recipients

  Serum samples were tested for antibody response using a glycoprotein enzyme-linked immunosorbent assay (gpELISA) in gamma-irradiated VZV vaccine A recipients. The geometric mean fold rise (GMFR) is the response at approximately 28 days postdose 4 / response predose on Day 1. This outcome measure applied only to participants who received VZV vaccine A; heat-treated VZV vaccine and placebo participants were not assessed for this outcome.

  Baseline and ~28 days Postdose 4 (~Day 118)

• Part 2: Geometric Mean Fold Rise of the VZV-Specific Immune Responses Measured by gpELISA in Gamma-Irradiated VZV Vaccine B Recipients

  Serum samples were tested for antibody response using gpELISA in gamma-irradiated VZV vaccine B recipients. The GMFR is the response at approximately 28 days postdose 4 / response predose on Day 1.

  Baseline and ~28 days Postdose 4 (~Day 118)

• Part 2: Geometric Mean Fold Rise of the VZV-Specific Immune Responses Measured by gpELISA in Gamma-Irradiated VZV Vaccine C Recipients

  Serum samples were tested for antibody response using gpELISA in gamma-irradiated VZV vaccine C recipients. The GMFR is the response at approximately 28 days postdose 4 / response predose on Day 1.

  Baseline and ~28 days Postdose 4 (~Day 118)

• Percentage of Participants With a Serious Adverse Event

  A serious adverse event (SAE) is defined as an adverse event that resulted in death, was life threatening, resulted in persistent or significant disability or incapacity, resulted in or prolonged a hospitalization, or is a congenital anomaly or birth defect. The percentage of participants with one or more SAEs was assessed.

  Up to ~28 days Postdose 4 (Up to ~118 days)

• Percentage of Participants With an Injection-Site Adverse Event Prompted on the Vaccination Report Card

  An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Vaccination Report Card (VRC)-prompted injection-site AEs included redness, swelling, and pain/tenderness/soreness. The percentage of participants with one or more VRC prompted injection-site AE was assessed with incidence \> 0% in one or more vaccination groups.

  Up to Day 5 post any vaccination (Up to ~5 days)

• Percentage of Participants With a Systemic Adverse Event Prompted on the Vaccination Report Card

  An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. VRC-prompted systemic AEs included non-injection-site varicella-like and herpes zoster (HZ)-like rashes. The percentage of participants with one or more VRC-prompted systemic AE was assessed with incidence \> 0% in one or more vaccination groups.

  Up to ~28 days Postdose 4 (Up to ~118 days)

• Percentage of Participants With Elevated Temperature Prompted on the Vaccination Report Card

  Elevated temperature is defined as ≥100.5 °F (≥38.1 °C), oral equivalent. The percentage of participants with VRC-prompted elevated temperature was assessed.

  Up to ~28 days Postdose 4 (Up to ~118 days)

• Percentage of Participants Who Discontinued the Study Drug Due to an Adverse Event

  An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who discontinued the study drug due to one or more AEs was assessed.

  Up to Dose 4 (Up to ~90 days)

Secondary Outcomes (1)

• Part 1: Geometric Mean Fold Rise of the Heat-Treated VZV-Specific Immune Responses Measured by gpELISA

  Baseline and ~28 days Postdose 4 (~Day 118)

Study Arms (5)

Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine

EXPERIMENTAL

Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine A; 4-dose regimen administered \~30 days apart.

Biological: Comparator: V212

Part 1: Gamma- Irradiated VZV Vaccine A

EXPERIMENTAL

Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \~30 days apart.

Biological: Comparator: V212

Part 1: Placebo

PLACEBO COMPARATOR

Participants received a 4-dose placebo regimen administered \~30 days apart.

Biological: Comparator: Placebo

Part 2: Gamma- Irradiated VZV Vaccine B

EXPERIMENTAL

Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \~30 days apart.

Biological: Comparator: V212

Part 2: Gamma- Irradiated VZV Vaccine C

EXPERIMENTAL

Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \~30 days apart.

Biological: Comparator: V212

Interventions

Comparator: V212 BIOLOGICAL

0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart

Part 1: Gamma- Irradiated VZV Vaccine A; Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine; Part 2: Gamma- Irradiated VZV Vaccine B; Part 2: Gamma- Irradiated VZV Vaccine C

Comparator: Placebo BIOLOGICAL

Placebo; 4-dose regimen administered \~30 days apart.

Part 1: Placebo

Eligibility Criteria

• Age: 50 Years - 59 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Must be 50 to 59 years of age
• No fever on vaccination days
• Must have had chickenpox or lived in an area where the chickenpox virus is prevalent for 30 or more years
• Females of child-bearing potential must use acceptable forms of birth control

You may not qualify if:

• Prior history of shingles
• Prior receipt of any chickenpox or shingles vaccine
• Pregnant or breastfeeding
• Received or expect to receive a live virus vaccine (such as measles, mumps, rubella) from 4 weeks before the first visit through the last visit
• Received or expect to receive an inactivated vaccine (such as tetanus or pneumonia) from 7 days before the first visit through the last visit
• Received immunoglobulin or blood products
• Receiving treatment that may weaken the immune system
• Have an immune system disorder

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

MeSH Terms

Conditions

Herpes Zoster

Condition Hierarchy (Ancestors)

Varicella Zoster Virus Infection; Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 11, 2008
• First Posted: June 13, 2008
• Study Start: December 12, 2008
• Primary Completion: November 16, 2009
• Study Completion: November 16, 2009
• Last Updated: November 8, 2019
• Results First Posted: November 8, 2019

Record last verified: 2019-10